Raising Capital Too Early: When Funding Comes Before Evidence
By Stephan Engelen · 2026-09-17
Some start-ups raise external capital before they have proved much more than their ability to tell a convincing story.
That is not, in itself, an argument against pre-seed or seed funding. In pharma, biotech, semiconductors and other research-intensive technologies, outside capital is often a prerequisite for creating evidence in the first place. Years of research, laboratories, clinical work, specialist talent, prototyping or highly expensive infrastructure may be required before there is even something meaningful to test commercially. In those businesses, capital finances the journey towards proof.
But that is not true for every start-up.
In many software, SaaS and business-model-driven companies, the most important early assumptions can be tested long before millions need to be raised. Is the problem real? Is it painful enough for somebody to pay to solve it? Are several customers buying for approximately the same reason? Can a customer who does not know the founder be convinced? Does each new deal make the proposition more repeatable, or does it require another exception?
Those questions are often relatively inexpensive to explore. And yet I increasingly see companies move very quickly from idea to fundraising, as though raising capital were itself part of validating the idea.
It isn't.
A financing round tells you that an investor believes the future may be valuable enough to justify the risk. It does not tell you that customers have validated the business, that the economics will work, or that what happened with the first three customers can be repeated with the next thirty.
That distinction becomes particularly important because capital does not simply give a young company more options. It can also protect it from questions that it would otherwise have been forced to answer.
When money is scarce, reality arrives quickly. If customers do not buy, something has to change. If every contract requires extensive customisation, the limits of the model become obvious. If the founder has to be involved in every sale, that dependence is difficult to hide. If acquiring a customer costs more than the customer is likely to be worth, there is very little room to pretend that this will somehow fix itself.
Once sufficient capital is available, those same weaknesses can be compensated for. More salespeople can be hired when sales are difficult. More marketing can fill the top of the funnel. More engineers can support customer-specific requests. More customer-success people can absorb complexity that perhaps should never have existed in the first place.
Revenue may go up. Headcount certainly goes up. From the outside, the company starts to look like it is scaling.
But sometimes it is not scaling a business.
It is scaling assumptions that have not yet been proven.
I have seen early traction interpreted too quickly as evidence of repeatability. This is understandable because founders are often exceptionally good at creating momentum before the system underneath it exists. They convince customers to buy something unfinished, attract employees before there is certainty and persuade investors to believe in an opportunity before the market is obvious.
That is one of the reasons companies get started.
It is also why the early numbers deserve careful interpretation. The first customers may partly be buying confidence in the founder. The product may be surrounded by more service than anyone admits. Deals may close because the founder knows exactly which argument to use or which exception to make. Revenue exists, but the mechanism behind the revenue is still largely personal.
There is nothing wrong with that at the beginning.
The mistake is calling it scale too early.
This is why I think the sequencing matters. Before asking how quickly a company can grow, there should be a period in which it deliberately reduces uncertainty. Not until every question has been answered — that never happens — but until there is enough evidence that the next phase will amplify something real.
You want to see customers outside the immediate founder network recognising the same problem. You want to see that customers are increasingly buying the same proposition rather than negotiating a different one every time. You want somebody other than the founder to sell it. You want the product to become easier to understand and easier to deliver rather than more complicated with every new customer.
Those may sound like modest milestones next to a financing round, but they tell you considerably more about the quality of the business.
There is also a second reason why I am cautious about raising too much, too early, particularly at an ambitious valuation. Funding changes the psychology of the organisation.
Before the round, most things are still allowed to be hypotheses. We think this is the customer. We think this is the problem. We think this price will work. We think this is how the product should evolve.
After a substantial round, those hypotheses start becoming commitments. People are hired against them. Budgets are built around them. The board expects milestones to be delivered against them. The valuation creates an expectation about what the company now has to become.
That makes it harder to discover that the original assumption was wrong.
A high valuation is therefore not always the gift it appears to be. It can become a poisoned gift if the business has not yet generated enough evidence to support the expectations attached to it. The company then starts growing into a valuation rather than growing out of what it has learned from the market.
That is a dangerous reversal.
The next round needs to justify the previous one. Growth targets become harder. Markets are entered because the plan requires it. People are hired because the growth curve requires it. Sales pressure increases because the story has to remain intact.
At exactly the moment when the company should still be learning, it becomes increasingly committed to proving that its early story was right.
I am not arguing for bootstrapping as an ideology, nor do I believe companies should wait until all uncertainty has disappeared before raising money. In many industries that would be impossible, and even in software there are moments when capital can fundamentally accelerate a good business.
The important distinction is simpler.
Some businesses need capital in order to create evidence.
Others raise capital before they have created evidence that was already cheap enough to obtain.
Those are not the same situation, and they should not be treated as if they were.
Capital is extraordinarily powerful when it accelerates something that is beginning to work. More sales capacity behind a repeatable sales motion can make sense. More marketing behind a proposition that clearly resonates can make sense. More engineering behind a product that customers increasingly depend on can make sense.
But capital cannot turn an assumption into evidence simply by allowing the assumption to grow faster.
That is why I would rather see founders celebrate the quieter milestones more seriously: the first customer who buys without a personal introduction, the first salesperson who consistently succeeds without the founder, the moment several customers describe essentially the same need, or the moment each additional customer makes the model more efficient rather than more complicated.
Those events rarely receive the attention of a funding announcement.
Yet they are the moments when a company actually earns the right to scale.
And once that evidence exists, external capital can do what it is supposed to do: increase the speed of something that has already started to work.
Raise before that point, and money may buy you time.
It may also buy you a much more expensive way of discovering that the original assumptions were wrong.